CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFECT OF VIRECHANA KARMA AND TRUSHNADI LOHA, LEKHANA BASTI AND TRUSHNADI LOHA AND DIET MANAGEMENT IN DYSLIPIDEMIA
- Conditions
- Health Condition 1: E784- Other hyperlipidemia
- Registration Number
- CTRI/2022/11/047337
- Lead Sponsor
- DR ASHWINI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1) Subjects of Dyslipidemia who have Total Cholesterol: 200-239 mg/dl, Serum Triglycerides:
150-499 mg/dl, Elevated Low Density Lipoprotein: 100-189 mg/dl53
, Low or Normal High
Density Lipoprotein: 35-59 mg/dl and Very Low Density Lipoprotein: >30mg/dl.
2) Patientâ??s having variations in any or all components of Lipid Profile will be taken for studies
3) Subjects irrespective of gender.
4) Subjects between the age group 25-60 years.
5) Subjects who are fit for Virechana Karma in Virechana intervention group.
6) Subjects who are fit for Lekhana Basti in Basti intervention group.
7) Diagnosed i.e., the patients who are already on Statins and fresh cases of Dyslipidemia will be
taken for the study. The definition of fresh cases includes:
ï?· Freshly detected and untreated cases of Dyslipidemia.
ï?· Established and treated cases of Dyslipidemia who have voluntarily discontinued the
treatment for at least 2 weeks before the case could be taken.
ï?· Established and treated cases of Dyslipidemia for whom treatment will be stopped and flush
out period of 2 weeks will be allowed before intervention.
1) Subjects having any systemic disorders which can interfere with the intervention.
2) Pregnant & Lactating women.
3) Alcoholic subjects will be excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To Know the effects of intervention on DyslipidemiaTimepoint: 8 weeks
- Secondary Outcome Measures
Name Time Method To evaluate if the Dyslipidemia condition is reversible through Rukshana Therapy and Dietary <br/ ><br>management. <br/ ><br>To standardize the safe and effective Ayurvedic line of management in Dyslipidemia in <br/ ><br>comparison to established drug in contemporary medicine.Timepoint: 8 weeks